[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"comorbidities-and-coexisting-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:comorbidities-and-coexisting-conditions":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,56,87,116,142,170,200,226,259,291,321,352,384,415,446,475,504,528,555,579,603],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":40,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100638424","ecardiacrehab---a-hybrid-patient-centered-ehealth-programme-100638424",false,"NCT07590635","eCardiacRehab - a Hybrid Patient-Centered eHealth Programme","eCardiacRehab - a Randomized Controlled Trial on a Hybrid Home-Based Patient-Centered eHealth Programme With Tailored Solutions","eCardiacRehab","Inclusion Criteria:\n\n* Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number\n* With coronary artery disease after percutaneous coronary intervention\n* Living at home\n* Have internet available\n* Provide signed informed consent\n\nExclusion Criteria:\n\n* Patients with cognitive impairment that may interfere with the ability to comply with the study protocol\n* Severe aortic stenosis\n* Severe arrhythmias\n* Expected lifetime less than one year as determined by study personnel\n* Otherwise clinically unstable\n* Not fully revascularized\n* Awaits percutaneous coronary intervention or coronary artery bypass graft surgery\n* Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy and cost effectiveness of an interdisciplinary and comprehensive home-based hybrid programme. eCardiacRehab address patient- and system level challenges to increase access to cardiac rehabilitation (CR). We give particular attention to older patients, women, and those with comorbidities or mental health challenges. The vision of the hybrid home-based eCardiacRehab programme is to make CR available to all.\n\neCardiacRehab is a prospective, multicentre randomized open-label blinded end point evaluation (PROBE) trial. The primary endpoint is a hierarchical composite endpoint using a win-ratio framework combining cardiovascular (CV) death, unplanned contacts to the Emergency Department (ED) for observation or admission (\\>24 hours) for CV disease, and quality of life. Inclusion criteria are adult Scandinavian speaking patients (≥ 18 years) who have a Norwegian national identification number, with CAD treated with Percutaneous Coronary Intervention (PCI), are living at home, and have internet available to them and providing signed informed consent. Exclusion criteria are patients with severe aortic stenosis, severe arrhythmias, expected lifetime less than one year as determined by study personnel, otherwise clinically unstable, not fully revascularized, awaits PCI or coronary artery bypass graft operation (CABG) or inability to comply with the study protocol due to any physical disability, somatic disease, cognitive impairment or mental health challenges as determined by study personnel.",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Comorbidities and Coexisting Conditions","Ethics","Continuity of Patient Care","Older Adults (65 Years and Older)","Cost-Benefit Analysis","Adherence, Medication","Secondary Prevention of Coronary Heart Disease","Health Literacy","eHealth Literacy","Mental Health","Cardiac Rehabilitation","Womens's Health","Coronary Artery Disease (CAD)",[37,41,42],"Coronary Artery Disease","Percutaneous Coronary Intervention","RECRUITING","2026-06-18",{"date":46,"type":47},"2026-06-23","ACTUAL",{"date":49,"type":47},"2026-05-21",{"date":51,"type":21},"2037-12-31",{"name":53,"class":54},"Haukeland University Hospital","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":55},"100470996","phase-2-evaluating-smoking-cessation-interventions-for-pwh-in-south-africa-100470996","NCT05413122","Evaluating Smoking Cessation Interventions for PWH in South Africa","Evaluating Smoking Cessation Interventions for PWH in South Africa: Efficacy, Implementation, and Cost-effectiveness","Tlogela","Inclusion Criteria:\n\n1. ≥18 years of age, and\n2. attend one of the selected study clinics, and\n3. have a confirmed diagnosis of HIV (evidenced by one of: clinic or hospital prescription for combination antiretroviral therapy (ART), or a current ART medication pack that has the patient's name documented thereon) and\n4. have been taking ART for at least three consecutive months or evidence of taking ART for four of the past six months (to ensure engagement in care at the recruitment clinic), and\n5. are current tobacco smokers (smoked at least 100 cigarettes in the subject's lifetime, smoked at least one cigarette daily in the past 30 days, have exhaled breath carbon monoxide (CO) ≥ 7 parts per million (ppm), and have a positive urine cotinine test), and\n6. either own or have household access to a mobile phone, and\n7. provide written informed consent.\n\nExclusion Criteria:\n\n1. Currently (within the previous 14 days) receiving or using smoking cessation counselling or pharmacotherapy, or\n2. are unable to participate due to severity of medical illness, guided by a Karnofsky score of ≤ 40, or\n3. have a history of seizures, cancer, heart disease, stroke, myocardial infarction, stomach ulcers, kidney failure, or liver failure, or\n4. have generalized eczema or psoriasis, or\n5. have cognitive dysfunction or psychosis as defined by the Mini-International Neuropsychiatric Interview (M.I.N.I.), or\n6. have suicide risk as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS), or\n7. are pregnant, planning to become pregnant in the next four months, lactating, or are unwilling to use effective birth control, or\n8. have a history of adverse reactions to varenicline or nicotine patch, or\n9. are not planning to continue to receive care at the clinic for the next 52 weeks, or\n10. are a household member of a currently enrolled participant in this trial, or\n11. In the opinion of the attending investigator are not a candidate for the clinical trail.",{"count":65,"type":21},660,[67,68],"PHASE2","PHASE3","The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.",[71,72,27],"Smoking Cessation","HIV",[71,74,75,76,77],"Combination NRT","Varenicline","Behavioral Counselling","Peer Counseling","2026-06-05",{"date":80,"type":47},"2026-06-09",{"date":82,"type":47},"2023-11-27",{"date":84,"type":21},"2027-08-31",{"name":86,"class":54},"Johns Hopkins University",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":55},"100547010","exploring-multimorbidity-in-patients-with-spinal-pain-100547010","NCT06402409","Exploring Multimorbidity in Patients With Spinal Pain","Workpackage 1: Baseline Prevalence and Implications of Multimorbidity for the Management of Spinal Pain Workpackage 2: The Influence of Multimorbidity Treatment Burden on Long-term Prognosis of Individuals With Spinal Pain","Inclusion Criteria:\n\n* 18 years old or above\n* Are diagnosed with neck or back pain\n* Diagnosis is established by or confirmed by a rheumatologist (clinical expert opinion)\n* Speak, read and understand Danish\n\nExclusion Criteria:\n\n* Withdraw consent",{"count":95,"type":21},2000,"1 Year","OBSERVATIONAL","Spinal pain is frequently accompanied by other chronic conditions (multimorbidity) and the predicted rise in multimorbidity prevalence emphasizes the need for studies to understand its impact on patients with chronic pain conditions.\n\nTherefore the aims of the two studies are to:\n\nWork package 1 - Determine prevalence of multimorbidity among patients with spinal pain referred to hospital outpatient clinics. Examine associations with relevant health-related factors and cover the significance of multimorbidity in the diagnostic process, referral patterns and healthcare utilization.\n\nWork package 2: Examine the association between treatment burden arising from multimorbidity and patient prognosis in structured rehabilitation.\n\nAcross both work packages data will be derived from individuals initially referred to the Department of Rheumatology at Aalborg University Hospital (AaUH) or the Medical Spine Clinic in Silkeborg (MSCS).",[100,101,27],"Back Pain","Neck Pain",[103,104,105,101,100,106],"Multimorbidity","Comorbidities","Comorbidity","Spinal pain","2026-04-09",{"date":109,"type":47},"2026-04-14",{"date":111,"type":47},"2024-04-01",{"date":113,"type":21},"2026-10-01",{"name":115,"class":54},"Jacob Christiansen Gandløse",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100633569","comorbidity-oriented-primary-care-and-integrated-management-for-hypertension-and-diabetes-mellitus-100633569","NCT07528391","Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus","Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus: A Cluster Randomised Controlled Trial in Rural China","COMPACT-HTDM","Inclusion Criteria:\n\nCluster level (primary care facilities):\n\n* Township health centers or community health service centers that provide routine primary care management services for both hypertension and diabetes.\n* Agree to participate in cluster randomization and study procedures.\n* Have basic capacity for chronic disease follow-up and data recording.\n\nIndividual participant level (patients):\n\n* Aged 60 to 74 years.\n* Diagnosed with hypertension and type 2 diabetes mellitus for at least 6 months.\n* Received at least one chronic disease management service at the participating study site within the past 6 months.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\nCluster Level (Primary Care Facilities):\n\n* Facilities currently participating in other intervention studies or pilot programs targeting hypertension and\u002For diabetes management that may interfere with the study intervention.\n* Facilities with major organizational instability (e.g., restructuring, closure, or significant staff turnover) that would affect implementation or follow-up.\n\nIndividual Level:\n\n* Severe cognitive impairment or psychiatric illness affecting participation or follow-up.\n* Anticipated inability to complete 6-month follow-up.","60 Years","74 Years",{"count":127,"type":21},960,[24],"The COMPACT-HTDM study is a parallel, two-arm cluster randomized controlled trial designed to evaluate a comorbidity-oriented integrated primary care management model for elderly patients with coexisting hypertension and type 2 diabetes mellitus in community health centers and township health centers. The trial aims to determine whether an integrated comorbidity management package can improve metabolic control and cardiovascular risk management compared with usual disease-specific care in routine primary care settings. Clusters are primary care facilities randomized 1:1 to intervention or control by an independent statistician using a computer-generated random sequence. Patients aged 60-74 years with diagnosed hypertension and type 2 diabetes for at least six months and recent use of chronic disease management services at the study site will be recruited through chronic disease registries. The intervention includes comorbidity-focused medication optimization and safety management, integrated lifestyle management, self-management and community support, training for primary care staff, standardized toolkits and workflow embedding, an integrated comorbidity management platform, and feedback\u002Fincentive mechanisms. The control group will continue current standard primary care management for hypertension and diabetes under existing national guidelines. Participants will be followed for six months, with possible extension to 12 months for longer-term outcomes. The primary outcome is the proportion of participants achieving both blood pressure and glycemic control targets, defined as SBP\u002FDBP \\\u003C130\u002F80 mmHg and HbA1c \\\u003C7.0%. Secondary outcomes include BMI, blood lipids, medication adherence, lifestyle behaviors, follow-up completion, referral rate, and safety events such as hypoglycemia and hypotension; implementation outcomes include acceptability, fidelity, and feasibility.",[131,132,27],"Hypertension","Diabete Type 2","NOT_YET_RECRUITING","2026-04-07",{"date":109,"type":47},{"date":137,"type":21},"2026-05-01",{"date":139,"type":21},"2028-12-31",{"name":141,"class":54},"Nanchang University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":55},"100615431","phase-2-tirzepatide-combined-with-cognitive-behavioural-therapy-cbt-for-adults-with-alcohol-use-disorder-aud-and-overweightobesity-oob-100615431","NCT07292519","Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight\u002FObesity (OOB)","Inclusion Criteria:\n\n1. Aged 21 to 75 years\n2. Meet DSM-5 criteria for alcohol use disorder (AUD) with at least moderate severity (≥4 symptoms in the past year)\n3. Have an average daily alcohol consumption of:\n\n   * ≥60g ethanol\u002Fday for men\n   * ≥40g ethanol\u002Fday for women (based on the 28 days prior to the baseline visit)\n4. Body mass index (BMI) ≥27 kg\u002Fm²\n5. Currently motivated to reduce or stop drinking but not engaged in formal AUD treatment\n6. Able and willing to attend weekly clinic visits and complete all study procedures\n7. Fluent in English and able to provide informed consent\n8. Stable housing situation (not transient or homeless)\n\nExclusion Criteria:\n\n1. Past-year DSM-5 diagnosis of another substance use disorder (except nicotine or mild cannabis use disorder)\n2. Recent (past 30 days) self-reported illicit drug use (excluding cannabis), or a positive urine drug screen for non-cannabis substances\n3. History of significant alcohol withdrawal, defined by:\n\n   * History of seizure, delirium tremens, or\n   * Hospitalisation for withdrawal, or\n   * CIWA-Ar score \\>9, or\n   * PAWS score \\>4 at screening\n4. Currently engaged in pharmacological or behavioral treatment for AUD, or prior engagement within the past 3 months\n5. History or current diagnosis of:\n\n   * Type 1 or Type 2 diabetes\n   * Diabetic complications (e.g. retinopathy)\n   * HbA1c ≥6.5% at screening\n6. Significant psychiatric illness, including:\n\n   * Current active suicidal ideation (per C-SSRS)\n   * Lifetime history of psychosis or bipolar disorder\n   * Unstable depression or anxiety interfering with daily functioning\n7. Chronic or acute pancreatitis\n8. Significant liver disease or abnormal liver function tests (ALT, AST, ALP, bilirubin \\>3× ULN)\n9. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type I\u002FII\n10. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\n11. Recent significant weight loss (\\>5% of body weight in past 30 days)\n12. Use of any weight loss medication (e.g., orlistat, bupropion-naltrexone) or AUD medication (e.g., naltrexone, acamprosate, topiramate, varenicline) in the past 3 months\n13. Use of tirzepatide or any GLP-1 receptor agonist in the past 6 months\n14. Pregnant or breastfeeding, or not using effective contraception (females of childbearing potential)\n15. Inability to attend weekly visits due to work\u002Ftravel\u002Fschedule conflicts\n16. Participation in another clinical trial involving an investigational product\n17. Shared household with a current or past participant in this trial\n18. Scheduled for surgery requiring anaesthesia within 90 days of enrolment that would interfere with participation or follow-up\n19. History of muscle wasting, bone disorders (e.g. sarcopenia)\n20. Active gastrointestinal conditions that could interfere with treatment (e.g., severe GERD)\n21. Uncontrolled hypertension, recent heart attack or stroke (within 6 months)\n\n    Extra Exclusion criteria for Those Participants Agreeing to Participate in Neuroimaging \\& Psychophysiology Tasks:\n22. Presence of any MRI-incompatible metal implants or devices, including pacemakers, aneurysm clips, insulin pumps, or cochlear implants\n23. History of brain surgery or penetrating head trauma\n24. Prior occupation as a machinist, welder, or metal worker (due to risk of metal fragments)\n25. Non-removable piercings or dental hardware that would interfere with MRI\n26. History of claustrophobia likely to interfere with scanning compliance aa. Neurological disorders (e.g., epilepsy, multiple sclerosis) likely to confound neuroimaging data bb. Inability to lie still or tolerate MRI procedures cc. Patient weighting over 159kg (MRI scan limit) dd. Any other condition or medication judged by the investigator to preclude safe participation","21 Years","75 Years",{"count":151,"type":21},46,[67],"The investigators approach is to conduct a Phase II Double-Blind randomised controlled trial with individuals with co-occurring Alcohol Use Disorder and overweight\u002Fobesity (AUD-OOB) to receive either a sub-cutaneous injection of Tirzepatide (2.5 mg for 4 weeks followed by 5 mg for 4 weeks) or visually matched sham saline injection, in combination with a structured behavioural intervention (Take Control CBT Module). The primary aim of the study is evaluate the efficacy of the intervention on the number of heavy drinking days (defined as 5+ standard drinks for men, 4+ standard drinks for women) during the final month of treatment (weeks 5 to 8) compared to baseline. The secondary aim of the study is to assess treatment effects on alcohol related (e.g. number drinks consumed per day, abstinent days) and cardio-metabolic outcomes (e.g. body weight in kg, waist circumference, blood pressure, HbA1c, total cholesterol etc...), and summarise safety outcomes associated with use (e.g. frequency and severity of side effects, number of serious adverse events, treatment related discontinuations). The study will also include neurobiological assessments such as functional magnetic resonance imaging (fMRI) and lab-based psychophysiology to assess the impact of tirzepatide on change in brain activity and autonomic responses to alcohol and food cues.",[155,156,27],"Alcohol Use Disorder (AUD)","Overweight or Obese",[155,156,158,159,160],"Concurrent Treatment of AUD and overweight\u002Fobesity","Tirzepatide","Phase II Double-blind RCT","2025-12-15",{"date":163,"type":47},"2025-12-18",{"date":165,"type":21},"2026-01-15",{"date":167,"type":21},"2028-01-15",{"name":169,"class":54},"South West Sydney Local Health District",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":55},"100611960","phase-1-ketamine-enhanced-therapy-for-individuals-with-alcohol-use-disorder-and-depression-a-pilot-study-ket-dual-100611960","NCT07247370","Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)","An Open-label Pilot Evaluation of Ketamine-Enhanced Psychotherapy in Individuals With Alcohol Use Disorder (AUD) and Co-morbid Major Depressive Disorder (MDD)","KET-DUAL","Inclusion Criteria:\n\n1. Moderate to severe AUD according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) criteria\n2. Presence of current Major Depressive Disorder (MDD), according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) criteria\n3. Expressed motivation to reduce or cease alcohol consumption.\n4. Consumed at least 21 standard drinks per week or 2 HDD per week (≥5 standard drinks\u002Fday for men; ≥4 for women) in the month prior to screening\n5. Age 18-70\n6. Adequate cognition and English language skills to give valid consent and complete research interviews\n7. Stable housing\n8. Willingness to give written informed consent.\n9. Willingness to comply with study procedures and attend scheduled visits.\n\nExclusion Criteria:\n\n1. DSM-5 diagnosis of current or past psychotic disorder, bipolar I disorder, or substance-induced psychosis.\n2. Current acute suicidality, defined as high risk by the Columbia Suicide Severity Rating Scale (C-SSRS) or clinical judgment or attempts in the past 6 months.\n3. DSM-5 diagnosis of current or past moderate-to-severe ketamine or other dissociative drug use disorder.\n4. Use of ketamine (prescribed or non-prescribed) in the previous 4 weeks.\n5. Enrolment in another interventional clinical trial that may interfere with safety, data quality, or trial participation.\n6. Pregnant or breastfeeding, or planning to become pregnant during the course of the study.\n7. Significant uncontrolled medical conditions, including but not limited to:\n\n   * Severe or poorly controlled hypertension (\\>160\u002F100 mmHg)\n   * Severe cardiovascular disease (e.g., heart failure, recent myocardial infarction, dysrhythmia)\n   * History of stroke, cerebral trauma, or intracranial mass\u002Fhaemorrhage\n   * Severe hepatic impairment (e.g., MELD ≥10) or end-stage liver disease, bladder or kidney disease\n8. Clinically significant alcohol withdrawal at screening (e.g., CIWA-Ar ≥10, history of delirium tremens).\n9. History of heightened intracranial pressure, seizures, or diagnosed seizure disorder (except childhood febrile seizures).\n10. Known hypersensitivity to ketamine or any excipients.\n11. Concurrent use of psychotropic medications (other than stable-dose antidepressants ≥4 weeks).\n12. Active substance use disorder (moderate or severe) other than nicotine or caffeine; stable opioid use disorder permitted if on maintenance therapy (with strict stability criteria).\n13. Inability or unwillingness to comply with study procedures, judged by the principal investigator.\n14. Any clinically significant medical or psychiatric condition that, in the judgment of the Principal Investigator, poses a safety risk or could confound study results or hinder protocol adherence.","70 Years",{"count":180,"type":21},20,[182,67],"PHASE1","To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.",[155,185,27],"Major Depressive Disorder (MDD)",[187,188,189,190,191,155,185],"Ketamine-enhanced psychotherapy","Open-label","Single-arm","Ketamine","Concurrent Treatment of AUD and comorbid MDD","2025-11-20",{"date":194,"type":47},"2025-11-25",{"date":196,"type":21},"2025-12-10",{"date":198,"type":21},"2027-12-10",{"name":169,"class":54},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":55},"100560597","comorbidity-management-in-rheumatic-disease-100560597","NCT06579222","Comorbidity Management in Rheumatic Disease.","Comorbidity Management in Rheumatic Disease: Assessing a Potential Care Gap in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Patients of the Waterloo Rheumatology Community Clinic\n* Aged 18 to 80 years of age\n* Diagnosis of rheumatoid arthritis\n* Minimum of limited working proficiency in English\n* No significant cognitive impairment that can inhibit their ability to engage in the study\n\nExclusion Criteria:\n\n* Age less than 18 years or greater than 80 years\n* Significant cognitive impairment that impedes ability to engage in the study\n* Unwilling to participate in the study\n* Patients currently pregnant will be excluded from the study","80 Years",{"count":209,"type":21},199,[24],"Rheumatoid arthritis is a disease where the immune system attacks the body by mistake, causing inflammation of the joints and other body parts. People with rheumatoid arthritis are at higher risk of infections, heart problems, and bone issues compared to others. They regularly see rheumatologists, arthritis care physicians, to manage their disease. However, managing these other health problems alongside their main treatment is difficult for rheumatologists due to limited resources. This clinical study is being conducted to see if adding a family doctor to a team of rheumatologists can help. Rheumatologists will complete a case report form about the patient's health and send them to a special family physician clinic. This clinic will focus on improving vaccination against diseases, heart health, and bone strength. They will check if patients need special vaccines to protect them from infections. They will screen for heart disease using blood pressure measurements, and order blood work for high cholesterol and diabetes if needed. They will also review bone health and send people for tests to check their bone density if needed. A change in routines and medications may be recommended after their checkup. Rheumatologists will complete another case report about the patient's health 6 months after their family doctor appointment. The study will assess how these markers of health management improve after this family doctor joins the team. It hopes to prove that this new way of working in the community will give people with rheumatoid arthritis better protection against certain infections, heart problems and weak bones.",[213,27],"Rheumatoid Arthritis",[215,216],"rheumatoid arthritis","comorbidities","2025-10-01",{"date":219,"type":47},"2025-10-07",{"date":221,"type":47},"2025-05-01",{"date":223,"type":21},"2026-12-19",{"name":225,"class":54},"Western University, Canada",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":244,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":55},"100483704","association-of-a-digital-signature-of-physical-activity-and-sedentary-lifestyle-with-the-development-of-multimorbidities-in-chronic-diseases-emob-100483704","NCT05578495","Association of a Digital Signature of Physical Activity and Sedentary Lifestyle With the Development of Multimorbidities in Chronic Diseases (eMOB)","Association of a Digital Signature of Physical Activity and Sedentary Lifestyle With the Development of Multimorbidities Over 4 Years of Follow-up in Chronic Diseases (eMOB) : a Prospective Cohort","eMOB","Inclusion Criteria:\n\n* Patient follow-up at CHU Clermont-Ferrand for a chronic disease in one of the following observational cohorts:\n\n  * Inflammatory rheumatic disease(rheumatoid arthritis, spondyloarthritis) included in the RCVRIC cohort (CPP Sud-Est VI N° ID-RCB- A01847-40)\n  * Pre-surgical knee and hip osteoarthritis (Evalmob) (ID-RCB N° 2019- A01017-50)\n  * Major depressive disorder included in the FACE-DR cohort (CNIL agreement: DR- 2015-673) and Bipolar disorder included in the FACE-BD cohort (CPP Ile de France IX; January 18, 2010) of the Adult Psychiatry Department B\n  * Type 2 diabetes included in the cohort of the sport medicine service \"Rehabilitation T2\" (CNIL agreement 0164)\n  * Obesity included in the \"Obesity\" sports medicine service cohort (CNIL agreement 0164)\n  * COPD included in the \"COPD Rehabilitation\" sports medicine service cohort (CNIL agreement 0164)\n  * Chronic pain cohort (eDOL) (CPP West II N° ID-RCB 2020-A02027-32)\n* Affiliation to a social security system.\n* Able to provide written informed consent to participate in the research.\n\nExclusion Criteria:\n\n* Inability to practice physical activity\n* Pregnant or breastfeeding\n* Refusal to participate\n* Minors or adults under the protection of the law or under the protection of justice.","90 Years",{"count":236,"type":21},700,[24],"Physical activity (PA) and sedentary lifestyle are determinants in the development of chronic diseases and associated quality of life alterations. PA levels are correlated with quality of life and morbidity in chronic lung disease (COPD), cardiovascular disease, diabetes, cancer, chronic inflammatory rheumatism, fibromyalgia and anxiety disorders. In these diseases, low-intensity PA often represents the main PA and the quantity of PA is correlated with health parameters.\n\nThis study aims to identify a typical profile (signature) in relation to the appearance of other chronic diseases, complications of your disease, from recording your physical activity and sedentary lifestyle by sensors evaluating very precisely the movements and taking into account the characteristics and disability related to your disease. The results of this study would therefore make it possible to identify this signature even before the appearance of complications or other diseases.",[240,241,242,27,105,103,243],"Exercise","Sedentary Behavior","Non Communicable Diseases","Digital Technology",[245,246,247,104,103,248,249],"Physical Activity","Sedentary Lifestyle","Chronic Diseases","Personal digital health","Personalized medecine","2025-09-19",{"date":252,"type":47},"2025-09-24",{"date":254,"type":47},"2023-12-07",{"date":256,"type":21},"2030-12",{"name":258,"class":54},"University Hospital, Clermont-Ferrand",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":267,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":276,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":55},"100486030","conversion-to-sadi-s-rygb-or-oagb-after-failed-sleeve-100486030","NCT05608772","Conversion to SADI-S, RYGB or OAGB After Failed Sleeve","Conversion of Failed Sleeve Gastrectomy Due to Weight Regain to SADI-S, RYGB or OAGB","RCTresleeve","Inclusion Criteria:\n\n* Undergone primary laparoscopic sleeve gastrectomy in the past\n* Weight regain\n\n  * defined as any increase in weight above the nadir as reported by the patient\n  * BMI at the time of revisional surgery was around 45 kg\u002Fm2\n  * weight regain was defined as an increase in BMI after bariatric surgery to exceed 35\n* With or without Gastroesophageal reflux disease (GERD) grade A and B o Patients with grade C or higher GERD, according to the Los Angeles (LA) classification \\[7\\] will be excluded from the study\n\nExclusion Criteria:\n\n* Didn't follow preoperative consultation\n* Cannot give of sign informed consent",true,{"count":269,"type":21},234,[24],"Assess what revisional surgery is superior and provides the best weight loss after primary LSG. What is the occurrence of complications and the nutritional laboratory status? And if the resolution and \u002For improvement of associated medical problems after the weight loss will occur.",[273,274,27,275],"Weight Loss","Bariatric Surgery Candidate","Nutrient Deficiency",[277,278,279,280],"RYGB","OAGB","SADI-S","Sleeve gastrectomy","2025-09-10",{"date":283,"type":47},"2025-09-16",{"date":285,"type":47},"2023-03-15",{"date":287,"type":21},"2028-04-15",{"name":289,"class":290},"General Committee of Teaching Hospitals and Institutes, Egypt","OTHER_GOV",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":178,"maxAge":299,"enrollmentInfo":300,"targetDuration":302,"studyType":97,"phases":4,"briefSummary":303,"conditions":304,"keywords":307,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":55},"100555087","frailty-in-outpatient-digestive-endoscopy-100555087","NCT06507527","Frailty in Outpatient Digestive Endoscopy","ASSESSMENT OF THE ADEQUACY IN CARE OF THE FRAGILE PATIENT IN A DIGESTIVE ENDOSCOPY UNIT FRIEND Study (FRailty In ENDoscopy) Estudi FRIEND (FRailty In ENDoscopy)","FRIEND","Inclusion Criteria:\n\n* It will include all patients over 70 years of age who are indicated to undergo an ambulatory upper or lower endoscopy.\n\nExclusion Criteria:\n\n* Age below 70 years\n* Non-ambulatory endoscopies\n* Assessment of test contraindications by the endoscopist\n* Non-acceptance to enter the study","100 Years",{"count":301,"type":21},1474,"16 Months","The increase in our society of the proportion of frail people who suffer from disability and dependency forces us to detect modifiable factors and therefore subject to intervention that can adapt health care for frail patients in order to increase the effectiveness and safety of medical treatments and procedures.\n\nA geriatric assessment should be performed on all patients likely to present frailty prior to a digestive endoscopy to assess the risk-benefit of the indication and to improve patient preparation by avoiding adverse effects of endoscopic examinations, increasing the safety and profitability of the tests There are no data in our medium on the prevalence of frailty in patients referred for endoscopy, nor on the incidence in these patients of adverse effects, inadequate preparations, or incomplete examinations, so a frailty study is needed to elaborate multidisciplinary protocols that improve circuits and care in these patients and prevent complications.\n\nThe questions we want to try to answer are:\n\n* Prevalence and severity of fragility in digestive endoscopy.\n* Specific problems related to fragility in digestive endoscopy, mainly the profitability of the examination and the incidence of adverse effects, in order to create protocols for improving care in this group of patients.",[305,27,306],"Frailty","Complication",[308,309,310,311],"Endoscopy","Indication","Bowell Preparation","Adverse effects","2025-07-28",{"date":314,"type":47},"2025-07-31",{"date":316,"type":47},"2024-06-10",{"date":318,"type":21},"2025-09-30",{"name":320,"class":54},"Parc de Salut Mar",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":330,"conditions":331,"keywords":340,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":55},"100571233","variation-in-drug-interactions-in-people-with-hiv-plwh-aged-60-years-and-older-100571233","NCT06717581","Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older.","Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older on Stable Antiretroviral Therapy Making a Switch to Bictegravir\u002FTenofovir Alafenamide\u002FEmtricitabine","Inclusion Criteria:\n\n* Age \\> 60 years\n* Non-infectious comorbidities receiving drug therapy\n* Receiving BIC\u002FTAF\u002FFTC therapy at the time of of enrollment\n\nExclusion Criteria:\n\n* Genotypic resistance testing that present or past evidence of viral resistance to the integrase inhibitor class, to emtricitabine or to tenofovir\n* Severe acute infectious disease",{"count":329,"type":21},50,"Several cohort studies have recently shown a significant increase in the mean age of PLWH ( People Living With HIV) and in the prevalence of people in advanced age in the various cohorts, as a result of the marked increase in the mean life expectancy of these people achieved by modern antiretroviral combination therapies.\n\nHowever, the high prevalence of comorbidities exposes PLWH in old age to the need to take multiple drug treatments in addition to antiretroviral therapy, with the gradually increasing risk of unfavorable pharmacokinetic interactions between antiretroviral drugs and drugs taken to treat the comorbidities.\n\nThis project consists of an observational, cohort, retrospective, single-center study and aims to evaluate the variation in the number and type of clinically significant drug interactions between antiretroviral therapy and concomitant therapies in PLWH aged \\>60 years on stable antiretroviral therapy who, for any reason at the Clinician's discretion, have made a switch from ongoing antiretroviral therapy to the bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide regimen.",[332,333,334,27,335,336,337,338,339],"HIV Infections","Drug Interaction","Elderly Infection","Cardiovascular Diseases","Metabolic Disease","Renal Disease","Osteoporosis Risk","Neoplasms",[72,341,342,104],"Drug Interactions","Retrovirus","2024-12-01",{"date":345,"type":47},"2024-12-05",{"date":347,"type":47},"2024-10-11",{"date":349,"type":21},"2025-10-11",{"name":351,"class":54},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":358,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":361,"conditions":362,"keywords":372,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":55},"100570688","histological-results-in-transgender-individuals-assigned-to-females-at-birth-undergoing-gender-affirmation-surgery-and-in-testosterone-therapy-100570688","NCT06710496","HISTOLOGICAL RESULTS IN TRANSGENDER INDIVIDUALS ASSIGNED TO FEMALES AT BIRTH UNDERGOING GENDER AFFIRMATION SURGERY AND IN TESTOSTERONE THERAPY","Inclusion Criteria:\n\n* gender incongruence diagnosis\n* people assigned female at birth\n* age \\>18 years\n* gender affirming surgery with hysterectomy\n* testosterone therapy\n\nExclusion Criteria:\n\n* previous gynecological surgery\n* previous gynecological disorder diagnosis","FEMALE",{"count":360,"type":21},100,"The aim of this study is to report histological results of genital organs removed during gender affirmg surgery in transgender people assigned female at birth (AFAB), to increase the knowledge about the long-term effects of gender affirming hormone therapy with testosterone on these organs and to evaluate the incidence of benign and malign gynecological pathology in AFAB transgender people.",[363,364,365,366,27,367,368,369,370,371],"Pregnancy","Smoking Behavior","Testosterone Replacement Therapy","Drugs","Gynecological Surgery","Transgender Men","Gender Affirmation Surgery","Hormone Replacement Therapy","Gynecological Disorders",[373,374,375],"transgender","afab","histology","2024-11-26",{"date":378,"type":47},"2024-11-29",{"date":380,"type":21},"2024-12",{"date":382,"type":21},"2025-12",{"name":351,"class":54},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":391,"targetDuration":393,"studyType":97,"phases":4,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":55},"100481838","integrated-multi-omics-data-for-personalized-treatment-of-obesity-associated-fatty-liver-disease-100481838","NCT05554224","Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease","Integrated Multi-omics and Machine Learning-driven Personalized Treatment of Obesity-associated Fatty Liver Disease","Inclusion Criteria:\n\n* Body mass index greater or equal to 40 kg\u002Fm\\^2.\n* Body mass index between 35 and 40 kg\u002Fm\\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus).\n* Positive psychiatric evaluation.\n* Age greater or equal to 18 years old.\n\nExclusion Criteria:\n\n* Legal or illegal drug consumption, including alcohol.\n* Diagnosis of Hepatitis.\n* Current cancer diagnosis or treatment.\n* Clinical or analytical evidence of severe illness.\n* Clinical or analytical evidence of chronic or acute inflammation.\n* Clinical or analytical evidence of infectious diseases.\n* Clinical or analytical evidence of terminal illness.",{"count":392,"type":21},1104,"10 Years","The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.",[396,397,27],"NAFLD","Obesity, Morbid",[399,400,401,402,403,404,405,406],"Weight loss","Bariatric surgery","Liver diseases","Mass spectrometry","Proteomics","Lipidomics","Metabolomics","Transcriptomics","2024-11-11",{"date":409,"type":47},"2024-11-13",{"date":411,"type":47},"2008-06-25",{"date":139,"type":21},{"name":414,"class":54},"Institut Investigacio Sanitaria Pere Virgili",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":423,"maxAge":207,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":433,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":55},"100512614","multidimensional-rehabilitation-programs-for-cognitive-impairment-in-comorbid-outpatients-a-randomized-controlled-trial-100512614","NCT05954741","Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial","Comparing the Effectiveness of Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial","RCTCogRehab","Inclusion Criteria:\n\n* Age Between 65 and 80 years.\n* Neurocognitive Disorder due to vascular disease with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \\\u003C 12 months.\n* Neurocognitive Disorder due to multiple etiology with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \\\u003C 12 months.\n\nExclusion Criteria:\n\n* Other known neurological conditions involving cognitive functioning (e.g. Parkinson's disease, Multiple Sclerosis, head trauma, alcohol abuse).\n* Severe organic instability.\n* Neoplasia in progress.\n* Severe psychiatric condition.\n* Illiteracy.\n* Severe perception deficits.\n* Severe motor disability.\n* Specific intellectual deficit.\n* Participation in other forms of training or neurostimulation in the previous 6 months.\n* Pharmacological interventions of neurological pertinence in the month before the study.","65 Years",{"count":425,"type":21},75,[24],"Dementias secondary to cerebrovascular diseases are of significant epidemiological and clinical relevance. As a result, the management of individuals with comorbid dementia should involve early diagnosis, effective treatment, and patient-centered care planning, both in specialist and in non-specialist settings. It is well known that physical exercise can improve various aspects of health, including resistance, balance, strength, and cognitive functions such as attention and executive performance. However, the efficacy of cognitive rehabilitation is still not definitive and requires further clarification. Preliminary evidence suggests that a combination of cognitive and motor training along with novel technological approaches has the potential to maintain or improve compromised cognitive function more effectively compared to a single intervention. A multidomain intervention could enhance cognitive functioning in elderly individuals with multiple morbidities. In the present study, patients with early neurocognitive impairment based on a vascular disorder or due to multiple etiologies, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, will be screened in an outpatient multidisciplinary setting and subsequently undergo different models of rehabilitation training.\n\nPrimary aim of this study:\n\n\\- Assess the effectiveness of different rehabilitation protocols for improving cognitive functions in patients with comorbid cognitive impairment. Specifically, the investigators will test the effectiveness of three rehabilitation protocols (digital-based cognitive rehabilitation combined with motor rehabilitation, paper-based cognitive rehabilitation combined with motor rehabilitation, and motor rehabilitation alone) by means of a set of multidimensional outcome measures.\n\nSecondary aims:\n\n\\- evaluating the enhancement of cognitive performance using various cognitive questionnaires categorized by cognitive domains. Additionally, the investigators will examine multidimensional variables such as motor skills, mood and anxiety levels, quality of life, patient adherence to treatment, the role of communication in patient management, caregiver burden, and the usability of digital devices (when utilized).",[429,430,27,431,432],"Cognitive Impairment","Dementia","Vascular Dementia","Dementia, Mixed",[430,105,434,435,436],"Cognitive rehabilitation","Motor rehabilitation","Digital-based cognitive rehabilitation","2024-10-01",{"date":439,"type":47},"2024-10-03",{"date":441,"type":47},"2024-02-29",{"date":443,"type":21},"2026-01",{"name":445,"class":54},"Istituti Clinici Scientifici Maugeri SpA",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":474},"100536042","a-mixed-method-pilot-investigation-of-paradoxical-intention-for-insomnia-100536042","NCT06259682","A Mixed-method Pilot Investigation of Paradoxical Intention for Insomnia.","A Mixed-method Pilot Investigation of Paradoxical Intention for Insomnia. Assessing Acceptability, Feasibility and Preliminary Effectiveness.","Inclusion Criteria:\n\n* Undergoing three screening phases: a web-based questionnaire, a telephone interview with a structured assessment, and a 7-day sleep diary completion.\n* Screening resulting in diagnosis of insomnia, including co-morbid insomnia.\n* Participant should fulfill the following DSM-5 criteria. (1)Difficulty in sleep Initiation, maintenance, or early morning awakening. (2)Frequency and duration of at least three nights per week and has been present for at least three months.(3) Problems persist despite candidates having had adequate opportunity and circumstances for sleep. (4) The sleep disturbance causes significant distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning.\n* Age above 18 and Swedish resident and language proficient.\n\nExclusion Criteria:\n\n* Severe depressive episode with suicidal intentions or actions\n* Current or past diagnosis of psychotic or bipolar disorders\n* Current substance use disorder\n* Recent changes in psychopharmacotherapy (within the last three months) or use of \"as-needed\" hypnotic medications during the trial.",{"count":454,"type":21},40,[24],"The investigators aim to test the preliminary efficacy as well as the acceptability and feasibility of paradoxical intention, which is a psychotherapeutic technique, for improving insomnia symptoms in adults. Previous research has tested this technique for insomnia and found overall positive results. However, during the last decades very few studies have examined paradoxical intention. Therefore the investigators wish to conduct a pilot study examining the effects in a modern context.",[458,27],"Insomnia",[460,461,462,463,464],"Insomnia disorder","mechanisms","mixed-methods","paradoxical intention","sleep performance anxiety","2024-08-14",{"date":467,"type":47},"2024-08-15",{"date":469,"type":21},"2024-09",{"date":471,"type":21},"2026-06",{"name":473,"class":54},"Örebro University, Sweden",3,{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":124,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":484,"conditions":485,"keywords":489,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":55},"100550792","postoperative-dietary-intake-of-hip-fracture-patients-100550792","NCT06451679","Postoperative Dietary Intake of Hip Fracture Patients","An Observation Study of Postoperative Dietary Intake of Older Adult Hip Fracture Patients: a Weighed Food Diary","Inclusion Criteria:\n\n* Adults \\>60yrs with a confirmed diagnosis of a hip fracture requiring surgical repair.\n\nExclusion Criteria:\n\n* Pathological hip fractures\n* Traumatic hip fractures - such as a road traffic collision injury.\n* Patients that cannot speak English due to the need for informed consent.\n* Patients undergoing oncologic treatment.",{"count":483,"type":21},30,"The goal of this observational study is to observe the postoperative dietary intake in older adult hip fracture patients from their day of surgery (day zero) until day three inclusive. The aims of this study are:\n\nPrimary aim:\n\nTo observe if the postoperative dietary energy intake (kJ\u002Fkcal) of older adult hip fracture patients meets Resting Energy Expenditure (REE) needs.\n\nSecondary aims:\n\nTo explore if there is a correlation between postoperative dietary intake and length of hospital stay.\n\nTo explore the relationship between comorbidity (where reported) and postoperative dietary intake, according to dietary intake.\n\nTo explore (if) in the development of postoperative complications (infection, pressure ulcer and VTE), there is a correlation with postoperative dietary intake.",[486,487,27,488],"Hip Fractures","Malnutrition","Postoperative Complications",[490,491,492,493,494],"Hip fracture","Perioperative","Surgical","Food diary","Nutrition","2024-06-24",{"date":497,"type":47},"2024-06-25",{"date":499,"type":47},"2024-05-13",{"date":501,"type":21},"2024-08-31",{"name":503,"class":54},"Teesside University",{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":55},"100552698","taiwan-interstitial-lung-disease-multi-center-investigation-and-registry-100552698","NCT06476470","Taiwan Interstitial Lung Disease Multi-center Investigation and Registry","A Prospective Multi-center Registry for Fibrotic Lung Disease, Focusing on Clinical Phenotype, Physical Parameters, Image Analysis, and Precision Medicine in Taiwan","TAILI","Inclusion Criteria:\n\n1. Aged over 18 years old.\n2. Diagnosed as ILD by a pulmonologist, rheumatologist or radiologist\n3. Various casue of ILD, including Idiopathic pulmonary fibrosis (IPF), Connective tissue disease-associated interstitial lung disease (CTD-ILD), Unclassifed ILD, drug-induced ILD, lymphangioleiomyomatosis (LAM), and sarcoidosis-associated ILD.\n\nExclusion Criteria:\n\n1. Under 18 years of age.\n2. Failure to express informed consent in person.",{"count":513,"type":21},10000,"The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease. This prospective observational registry will collect comprehensive clinical data from multiple centers, including epidemiological information, comorbidities, questionnaire results, routine blood tests, biochemical tests, pulmonary function tests, echocardiograms, and cardiopulmonary exercise tests (CPET), all following a standardized protocol.\n\nKey components of the registry include annual HRCT scans, annual CPETs, biobank blood samples, and biannual echocardiograms and pulmonary function tests.\n\nThe main questions the registry aims to answer are:\n\n1. Differences in all-cause mortality among ILD patients of different etiologies.\n2. Differences in the annual risk of acute exacerbation among ILD patients of different etiologies.\n3. Effectiveness of current anti-fibrotic drugs in treating IPF and ILD of different etiologies.\n4. Predictive ability of HRCT imaging features for mortality risk in ILD patients.\n5. Impact of comorbidities on the mortality risk of ILD patients.\n6. Predictive ability of biomarkers for disease progression and mortality.",[516,27,517,518,519],"Interstitial Lung Disease","Pulmonary Arterial Hypertension","Treatment Adherence","Function Impaired Respiratory",{"date":521,"type":47},"2024-06-26",{"date":523,"type":47},"2024-03-10",{"date":525,"type":21},"2035-12-31",{"name":527,"class":54},"Taichung Veterans General Hospital",{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":17,"minAge":535,"maxAge":4,"enrollmentInfo":536,"targetDuration":538,"studyType":97,"phases":4,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":4},"100551181","xishui-project-for-idm-of-copd-and-comorbidities-100551181","NCT06456749","Xishui Project for IDM of COPD and Comorbidities","An Observational, Prospective Study on the Integrated Disease Management Effectiveness of COPD and Related Comorbidities in Xishui","Inclusion Criteria:\n\n* Aged ≥40 years;\n* Stable COPD patients with post-bronchodilator FEV1\u002FFVC \\\u003C70% or previously diagnosed of COPD by physicians and confirmed by PFT;\n* With\u002Fwithout diabetes and\u002For hypertension;\n* Permanent resident of Xishui (not expected to leave the area within 1 year).\n\nExclusion Criteria:\n\n* Suffering from severe cognitive disorders or total loss of ability of daily living.\n* Death.","40 Years",{"count":537,"type":21},4000,"12 Months","Study Population: 4000 stable COPD patients, and among them approximately 2000 subjects with hypertension and\u002For type 2 diabetes complications.\n\nDesign: Cohort Study Primary Objectives: The primary objective of this study is to access the effectiveness of IDM on changes in FEV1 from baseline to the 24th week visit in patients with COPD.\n\nStatistical Analysis: We plan to compare demographic differences between groups based on whether the data conformed to normal distribution and satisfied variance chi-square, and proposed to calculate p-values using the t-test or non-parametric test for continuous data and Person's χ² or non-parametric test for categorical data. A two-sided p-value \\\u003C 0.05 is considered statistically significant.",[541,27],"Chronic Obstructive Pulmonary Disease",[543,544,545],"Effectiveness of Integrated Disease Management","Multimorbidity Management","Prosepective Cohort Study","2024-06-12",{"date":548,"type":47},"2024-06-13",{"date":550,"type":21},"2024-06-17",{"date":552,"type":21},"2026-03-15",{"name":554,"class":54},"China-Japan Friendship Hospital",{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":538,"studyType":97,"phases":4,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":575,"leadSponsor":577,"locationsCount":55},"100461992","giessen-stroke-registry-100461992","NCT05295862","Giessen Stroke Registry","Giessen Acute Stroke Registry","GIST","Inclusion Criteria:\n\n* Age above 18\n* Patient admitted for acute stroke (Stroke Unit or Intensive Care Unit)\n* Informed Consent\n\nExclusion Criteria:\n\n* Inclusion criteria not met",{"count":95,"type":21},"The aim of the planned study project is to assess the current situation regarding the treatment of patients with stroke. Specifically, various treatment strategies are to be associated and correlated with clinical endpoints, mortality or functional outcome in order to generate arguments for or against individual aspects of therapy. The focus will be on unresolved treatment approaches in acute therapy (e.g. periprocedural management, such as blood pressure, blood glucose, temperature, or airway management, during recanalizing therapies) as well as in secondary prevention on the stroke unit or intensive care unit, such as starting point, mode, and dosage of antithrombotic therapies.",[566,27,567],"Stroke, Acute","Critical Care",[569,104,570],"Acute Stroke","Clinical Management","2023-11-30",{"date":573,"type":47},"2023-12-01",{"date":571,"type":47},{"date":576,"type":21},"2027-12-31",{"name":578,"class":54},"University of Giessen",{"id":580,"slug":581,"hasResults":11,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":588,"conditions":589,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":55},"100484250","registry-for-hypoparathyroidism-wuerzburg-100484250","NCT05585593","Registry for Hypoparathyroidism Wuerzburg","Registry and Biobank for Patients With Hypoparathyroidism Wuerzburg","Inclusion Criteria:\n\n* age of 18\n* chronic hypoparathyroidism (\\>12 months) under established therapy or chronic pseudohypoparathyroidism (\\>12 months) under established therapy\n* written informed consent\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* no detailed documentation of hypo- or pseudohypoparathyroidism",{"count":587,"type":21},300,"Long-term conventional treatment of chronic hypoparathyroidism does not fully restore calcium homeostasis leading to increased morbidity, emergency events and reduced subjective health status. To further investigate general morbidity, hypocalcemic events, subjective and daily life performance in patients with chronic hypoparathyroidism a standardized interview as well as blood sampling and examinations such as echocardiography and renal ultrasound are performed.",[27,590,591,592,593],"Morality","Hypocalcemia","Hypercalcemia","Quality of Life","2022-11-02",{"date":596,"type":47},"2022-11-08",{"date":598,"type":47},"2017-10-18",{"date":600,"type":21},"2032-01-01",{"name":602,"class":54},"University of Wuerzburg",{"id":604,"slug":605,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":22,"phases":612,"briefSummary":613,"conditions":614,"keywords":616,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":55},"100475591","the-banded-mini-gastric-bypass-trial-a-prospective-randomized-controlled-trial-100475591","NCT05472922","The Banded Mini Gastric Bypass Trial: A Prospective Randomized Controlled Trial","RiMini","Inclusion Criteria:\n\n* Patients meet IFSO criteria for Bariatric Surgery\n* Age 18 and above\n\nExclusion Criteria:\n\n* Previous Bariatric surgery\n* Inability to read and understand written information\n* Any genetic condition that can hamper the acceptance of medical advice\n* chronic bowel disease\n* Severe kidney of liver disease\n* Pregnancy at the start or during the research period\n* Patients with pre-existing therapy refractory GERD\n* Patients with an allergy to silicone",{"count":611,"type":21},210,[24],"Rationale: Investigate if there is a significant weight reduction expressed in total body weight loss percentage (%TBWL) in patients 5 years after surgery, whom underwent a mini gastric bypass (MGB-OAGB) with addition of the implantation of a MiniMizer Ring.\n\nStudy design: A prospective non blinded single centre randomized controlled trial.\n\nSudy population: The study population will exist of patients eligible for MGB-OAGB surgery. Patients are invited to participate if Body Mass Index (BMI) ≥ 35kg\u002Fm2 with a comorbidity related to morbid obesity, or a BMI exceeding 40kg\u002Fm2.\n\nIntervention: Insertion of the MiniMizer Ring around the gastric pouch in addition to the 'standard' MGB-OAGB.\n\nMain study parameters\u002Fendpoints:\n\nPrimary Objective:\n\n1. %TBWL 5 years after surgery.\n\n   Secondary Objectives:\n2. Percentage Excess Weight Loss (%EWL) 5 years after surgery.\n3. Decrease or reduction of comorbidities (diabetes mellitus, hypertension, hyperlipidemia, sleep apnoea, and joint complaints).\n4. Improvement of quality of life: SF-36 and OBESI-Q questionnaires.\n5. Incidence and severity of dumping syndrome.\n6. Incidence and severity of reflux symptoms: GERD-HRQoL questionnaire.\n7. Incidence and complications due to silicone band.\n\nMeasurement of objectives are before surgery and six times after surgery combined with the standard postoperative care for patients who undergo bariatric surgery:\n\nExpected advantages of bOLGB versus OLGB:\n\n1. Increase of weight reduction, and due to that decrease of comorbidities and\u002For mortality related to overweight.\n2. Long term decrease of weight regain.\n3. Decrease of incidence of dumping.\n\nPossible disadvantages of bOLGB versus OLGB:\n\n1. Band-related complications such as erosion, infection, stenosis, or pouch dilatation.\n2. Functional gastro-intestinal complains such as dysphagia and reflux.",[615,273,27],"Bariatric Surgery",[617,618,619],"MGB-OAGB","MiniMizer Ring","banded bypass","2022-07-20",{"date":622,"type":47},"2022-07-25",{"date":624,"type":47},"2022-07-01",{"date":626,"type":21},"2028-07-01",{"name":628,"class":54},"Marc van Det"]